Published in Eur Respir J on April 08, 2009
Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J (2011) 1.26
Gaps in using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites. Int J Tuberc Lung Dis (2015) 1.22
COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis (2014) 1.11
The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur J Epidemiol (2015) 1.06
The impact of COPD on health status: findings from the BOLD study. Eur Respir J (2013) 1.01
Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J Chron Obstruct Pulmon Dis (2010) 1.01
Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respir Med (2010) 0.89
New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses. Pharmacoeconomics (2012) 0.86
Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend. Am Health Drug Benefits (2014) 0.86
Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLoS One (2011) 0.83
Expert Nordic perspectives on the potential of novel inhalers to overcome unmet needs in the management of obstructive lung disease. Eur Clin Respir J (2015) 0.81
The prevalence of COPD co-morbidities in Serbia: results of a national survey. NPJ Prim Care Respir Med (2014) 0.78
Raising the awareness: projecting the future burden of COPD with the BOLD model. Eur Respir J (2009) 0.77
The Role of Mitochondria and Oxidative/Antioxidative Imbalance in Pathobiology of Chronic Obstructive Pulmonary Disease. Oxid Med Cell Longev (2016) 0.76
Productivity losses in chronic obstructive pulmonary disease: a population-based survey. BMJ Open Respir Res (2014) 0.76
Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France. PLoS One (2016) 0.75
"Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD. BMC Pulm Med (2010) 0.75
Pulmonary rehabilitation coupled with negative pressure ventilation decreases decline in lung function, hospitalizations, and medical cost in COPD: A 5-year study. Medicine (Baltimore) (2016) 0.75
Respiratory symptoms increase health care consumption and affect everyday life - a cross-sectional population-based study from Finland, Estonia, and Sweden. Eur Clin Respir J (2016) 0.75
New evidence of increased risk of rhinitis in subjects with COPD: a longitudinal population study. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Risk stratification for COPD diagnosis through an active search strategy in primary care. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Exacerbations and health care resource utilization in patients with airflow limitation diseases attending a primary care setting: the PUMA study. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41
Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med (1999) 29.97
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA (1994) 10.46
International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet (2007) 10.12
Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax (2003) 4.81
An introduction to Markov modelling for economic evaluation. Pharmacoeconomics (1998) 4.27
Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J (2002) 3.06
The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD (2005) 2.66
A dynamic population model of disease progression in COPD. Eur Respir J (2005) 2.59
Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health (2005) 2.32
The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med (2002) 2.29
Smoking cessation during previous year among adults--United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep (1993) 2.26
Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med (2006) 2.15
The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med (2001) 1.96
Economic analysis of the Confronting COPD survey: an overview of results. Respir Med (2003) 1.93
Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax (1991) 1.79
Nonresponse in a community cohort study: predictors and consequences for exposure-disease associations. J Clin Epidemiol (2002) 1.75
Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity. Pharmacoeconomics (1999) 1.71
Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med (2004) 1.64
Costs of COPD in Sweden according to disease severity. Chest (2002) 1.52
Can economic evaluations be made more transferable? Eur J Health Econ (2005) 1.27
Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. Int J Tuberc Lung Dis (2005) 1.19
A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health (2004) 1.17
The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med (2000) 1.16
The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls. Respir Med (2006) 1.11
The 1990 Report of the Surgeon General: The Health Benefits of Smoking Cessation. Am Rev Respir Dis (1990) 1.06
Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med (2000) 0.99
Direct medical cost of chronic obstructive pulmonary disease in the U.S.A. Respir Med (2000) 0.99
Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2006) 0.96
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med (2001) 27.83
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA (1994) 10.46
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med (1992) 8.53
Global burden of COPD: systematic review and meta-analysis. Eur Respir J (2006) 7.00
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash) (2001) 5.03
Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax (2003) 4.81
Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J (2006) 3.89
Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med (2000) 3.43
Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest (1999) 3.28
Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA (1999) 3.24
The economic burden of COPD. Chest (2000) 3.21
A new perspective on concepts of asthma severity and control. Eur Respir J (2008) 3.16
Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest (2000) 3.12
The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol (2001) 3.08
Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J (2002) 3.06
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax (2005) 2.69
A dynamic population model of disease progression in COPD. Eur Respir J (2005) 2.59
An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax (2004) 2.54
Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J (2009) 2.52
Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J (2005) 2.51
Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol (2000) 2.48
Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J (1999) 2.44
The costs of treating COPD in the United States. Chest (2001) 2.43
Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med (1999) 2.36
Specialty differences in the management of asthma. A cross-sectional assessment of allergists' patients and generalists' patients in a large HMO. Arch Intern Med (1997) 2.28
Increase in diagnosed asthma but not in symptoms in the European Community Respiratory Health Survey. Thorax (2004) 2.23
Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis (2005) 2.21
Gender differences in smoking cessation after 3 years in the Lung Health Study. Am J Public Health (1995) 2.16
Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA (1999) 2.12
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med (1994) 2.11
Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med (2001) 2.06
Parental smoking in childhood and adult obstructive lung disease: results from the European Community Respiratory Health Survey. Thorax (2004) 1.99
Spirometry in the Lung Health Study. 1. Methods and quality control. Am Rev Respir Dis (1991) 1.99
Predicted values for closing volumes using a modified single breath nitrogen test. Am Rev Respir Dis (1973) 1.89
Allelic frequencies and patterns of single-nucleotide polymorphisms in candidate genes for asthma and atopy in Iceland. Am J Respir Crit Care Med (2001) 1.89
Absence of relationship between tuberculin reactivity and atopy in BCG vaccinated young adults. Thorax (2000) 1.88
The medical cost of undiagnosed sleep apnea. Sleep (1999) 1.86
Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Baseline characteristics of randomized participants. Chest (1993) 1.85
Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis (1993) 1.82
Increased mortality among sleepy snorers: a prospective population based study. Thorax (1998) 1.82
Insomnia in men-a 10-year prospective population based study. Sleep (2001) 1.81
Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax (1991) 1.79
Sleep and sleep habits from childhood to young adulthood over a 10-year period. J Psychosom Res (2002) 1.76
Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration. Chest (1994) 1.71
Preventing deaths from asthma. N Engl J Med (1994) 1.70
Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax (2008) 1.68
CTLA4 gene polymorphisms are associated with chronic bronchitis. Eur Respir J (2009) 1.62
Sleep disturbances in a young adult population: can gender differences be explained by differences in psychological status? Sleep (1997) 1.62
Quantitative computed tomography: emphysema and airway wall thickness by sex, age and smoking. Eur Respir J (2009) 1.61
Decline in FEV1 and airflow limitation related to occupational exposures in men of an urban community. Eur Respir J (1993) 1.61
Total and specific serum IgE levels in adults: relationship to sex, age and environmental factors. Clin Exp Allergy (1994) 1.60
Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease? Int J Tuberc Lung Dis (2009) 1.60
Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax (2005) 1.58
An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. J Am Board Fam Pract (1999) 1.58
Management of obstructive sleep apnea in Europe. Sleep Med (2010) 1.56
Quantitative analysis of the alveolar plateau in the diagnosis of early airway obstruction. Am Rev Respir Dis (1973) 1.56
Restricted spirometry in the Burden of Lung Disease Study. Int J Tuberc Lung Dis (2012) 1.55
Characteristics of patients with asthma within a large HMO: a comparison by age and gender. Am J Respir Crit Care Med (1998) 1.53
Relative impact of smoking and reduced pulmonary function on peptic ulcer risk. A prospective study of Japanese men in Hawaii. Gastroenterology (1989) 1.52
Role of snoring and daytime sleepiness in occupational accidents. Am J Respir Crit Care Med (2001) 1.50
Predictors for PaO2 and hypoxemic respiratory failure in COPD-A three-year follow-up. COPD (2014) 1.49
Monitoring recruitment effectiveness and cost in a clinical trial. Control Clin Trials (1993) 1.49
Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother (1997) 1.48
The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. Arch Intern Med (2000) 1.48
Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis (1999) 1.46
Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. Thorax (2010) 1.46
Cigarette smoking gives more respiratory symptoms among women than among men. The Nord-Trondelag Health Study (HUNT). J Epidemiol Community Health (2000) 1.44
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ (2004) 1.42
Associations of smoking with hospital-based care and quality of life in patients with obstructive airway disease. Chest (1999) 1.42
COPD exacerbations: the importance of a standard definition. Respir Med (2004) 1.42
Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med (1994) 1.42
Recruiting hard-to-reach subjects: is it worth the effort? Control Clin Trials (1994) 1.41
Postal survey on airborne occupational exposure and respiratory disorders in Norway: causes and consequences of non-response. J Epidemiol Community Health (1990) 1.41
Polyclonal human antibodies to IgG (rheumatoid factors) which cross-react with cell nuclei. Scand J Immunol (1976) 1.41
Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med (1995) 1.40
20-year trends in the prevalence of asthma and chronic airflow obstruction in an HMO. Am J Respir Crit Care Med (1998) 1.40
The role of habitual snoring and obesity in the development of diabetes: a 10-year follow-up study in a male population. J Intern Med (2000) 1.40
Revisiting the cost-effectiveness of omalizumab. Allergy (2007) 1.40
Total serum IgE and FEV1 by respiratory symptoms and obstructive lung disease in adults of a Norwegian community. Clin Exp Allergy (1995) 1.40
Showing outcomes and proving value brings success. Manag Care Interface (2001) 1.39
Somatic diseases and sleep complaints. An epidemiological study of 3,201 Swedish men. Acta Med Scand (1987) 1.39
The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol (1999) 1.39
Sex differences in lung vulnerability to tobacco smoking. Eur Respir J (2003) 1.38
Trends in symptoms of obstructive lung disease in Norway. Int J Tuberc Lung Dis (2004) 1.38
Long-term changes in adult asthma prevalence. Eur Respir J (2003) 1.38
Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trøndelag Study. Eur Respir J (2001) 1.37
Caesarean section delivery and the risk of allergic disorders in childhood. Clin Exp Allergy (2005) 1.36
C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study. Thorax (2005) 1.33
Sleep-disordered breathing and glucose metabolism in hypertensive men: a population-based study. J Intern Med (2001) 1.33
Obesity and nocturnal gastro-oesophageal reflux are related to onset of asthma and respiratory symptoms. Eur Respir J (2004) 1.30
A comparison of conventional spirometric tests and the test of closing volume in an emphysema screening center. Am Rev Respir Dis (1973) 1.30
Bronchial responsiveness in a Norwegian community. Am Rev Respir Dis (1991) 1.29
Prospective study of pulmonary function and lung cancer. Am Rev Respir Dis (1991) 1.29